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Abstract
Background—Associations between carotenoid intake and prostate cancer (CaP) incidence have 
varied across studies. This may be due to combining indolent with aggressive disease in most 
studies. This study examined whether carotenoid intake and adipose tissue carotenoid levels were 
inversely associated with CaP aggressiveness.
Methods—Data on African-American (AA, n=1,023) and European-American (EA, n=1,079) 
men with incident CaP from North Carolina and Louisiana were analyzed. Dietary carotenoid 
intake was assessed using a detailed food frequency questionnaire, and abdominal adipose tissue 
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samples were analyzed for carotenoid concentrations using high-performance liquid 
chromatography. Multivariable logistic regression was used in race-stratified analysis to calculate 
odds ratios (ORs) and 95% confidence intervals (95%CI) comparing high aggressive CaP with 
low/intermediate aggressive CaP.
Results—Carotenoid intake differed significantly between AAs and EAs, which included higher 
intake of lycopene among EAs and higher β–cryptoxanthin intake among AAs. Comparing the 
highest and lowest tertiles, dietary lycopene was associated inversely with high aggressive CaP 
among EAs (OR=0.55, 95%CI: 0.34–0.89, Ptrend=0.02), while an inverse association was observed 
between dietary β–cryptoxanthin intake and high aggressive CaP among AAs (OR=0.56, 95%CI: 
0.36–0.87, Ptrend=0.01). Adipose tissue α–carotene and lycopene (cis + trans) concentrations were 
higher among EAs than AAs, and marginally significant inverse linear trends were observed for 
adipose α–carotene (Ptrend=0.07) and lycopene (Ptrend=0.11), and CaP aggressiveness among EAs 
only.
Conclusions—These results suggest that diets high in lycopene and β–cryptoxanthin may 
protect against aggressive CaP among EAs and AAs, respectively. Differences in dietary behaviors 
may explain the racial differences in associations.
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Introduction
Prostate cancer (CaP) remains the most commonly occurring invasive malignancy and the 
second leading cause of cancer death among American men (1). Accumulated data on the 
relation between diet and cancer incidence indicate that about 30–40% of all cancer cases 
may be preventable through healthy diet and weight control (2,3). Greater intake of 
vegetables and, to a lesser extent, fruits has been associated with lower risk of various 
malignancies, which include CaP (4,5). However, identifying the beneficial nutrients or 
bioactive compounds responsible for the suggested protection conferred by vegetables and 
fruit intake against CaP remains a challenge. Carotenoids are biologically active 
phytochemicals found in many plant foods, and they are thought to contribute to the inverse 
association between vegetables and fruit intake and CaP risk (5,6). Despite this evidence, 
findings from case-control and cohort studies summarized in recent reviews (7,8) indicate 
that the overall association between carotenoid intake and CaP risk is equivocal.
Lycopene and β–carotene are the most commonly studied carotenoids in relation to CaP. 
Lycopene, a carotenoid devoid of vitamin A activity, has the strongest evidence for 
beneficial association with CaP (9–12), although study results have varied (13,14). Early 
studies focused primarily on β–carotene, a pro-vitamin A carotenoid; however, two large 
intervention trials conducted in Finland (15) and in the United States (16) failed to show a 
beneficial effect of β–carotene supplementation on CaP incidence in secondary analyses. 
One reported a 23% increased risk of CaP in the β–carotene intervention group versus 
placebo (15), and the other, which examined effects of β–carotene and retinol supplements 
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in tandem because of their close metabolic relationship, found a 52% increased risk of 
aggressive CaP (Gleason ≥7 or stage III/IV) in the intervention group compared to placebo 
(16). The elevated risks associated with β–carotene supplementation were not evident in 
follow-up studies (16,17), and observational studies have conflicted on associations between 
β–carotene and CaP risk (6–8). Carotenoids, such as α–carotene, β–cryptoxanthin, lutein, 
and zeaxanthin, have been associated with modest reductions in CaP risk, but as with 
lycopene and β–carotene, findings have been mixed (18–20).
Data are scarce on the relationship between carotenoid intake and CaP aggressiveness (as 
opposed to overall CaP incidence) (9,14). As suggested by Giovannucci et al. (12), the 
dietary risk factors for aggressive CaP may differ from those for non-aggressive disease, and 
thus, some carotenoids may differentially influence aggressive versus non-aggressive CaP. 
Given the inconsistent findings, and increased interest in identifying modifiable risk factors 
for aggressive CaP, particularly among African Americans (AAs), a population with a high 
incidence of aggressive CaP (21), this study investigated associations of dietary, 
supplemental and adipose tissue carotenoid levels in relation to CaP aggressiveness among 
AA and European-American (EA) men in North Carolina and Louisiana.
Materials and Methods
Research Subjects
A population-based, case-control study was conducted using data from the North Carolina-
Louisiana Prostate Cancer Project (PCaP). One of the primary aims of PCaP, a 
multidisciplinary, cross-sectional, case-only, incident CaP study, was to investigate and 
compare factors associated with CaP aggressiveness among AAs and EAs. Residents of the 
study catchment areas in North Carolina and Louisiana were eligible to participate in PCaP 
if they had a first, histologically confirmed, diagnosis of adenocarcinoma of the prostate 
between July 1, 2004 and August 31, 2009, were 40–79 years of age at the time of diagnosis, 
and self-identified their race as AA/Black or “Caucasian American”/White (EA). Other 
eligibility criteria included having sufficient cognitive and physical functions to consent and 
complete the study interview in English, and not residing in an institution (e.g., nursing 
home). PCaP enrolled 2267 research subjects of whom approximately half were EAs (n= 
1130) and half were AAs (n = 1137). All research subjects provided written informed 
consent before participating in the study. Participation rates were 62% in North Carolina, 
72% for pre-Hurricane Katrina Louisiana and 63% for post-Hurricane Katrina Louisiana. 
Further details of the PCaP methods and design can be found elsewhere (22). The PCaP 
study protocols were approved by Institutional Review Boards of all collaborating 
institutions (22), and the current study also received Institutional Review Board approval 
from the University of South Carolina.
Data Collection
Structured, in-person interviews were conducted by trained research nurses, usually in the 
home of the research subject or at a place of his choosing. Trained interviewers solicited 
information that included demographic and socioeconomic factors, personal health history, 
family history of CaP, pre-diagnostic CaP screening habits, comorbidities, smoking history, 
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physical activity, usual diet, and use of dietary supplements and non-steroidal anti-
inflammatory drugs (NSAIDs). Research nurses obtained measurements of research 
subjects’ height and weight at the end of each interview using a standardized protocol. 
Information on the clinical stage, Gleason sum and prostate-specific antigen (PSA) level at 
diagnosis as well as disease-directed treatments were extracted from the research subjects’ 
medical records that were obtained from diagnosing physicians. Watchful waiting (i.e., 
active surveillance of the progression of CaP) was not considered as a form of treatment in 
this study. The medical record abstractions were performed by trained personnel and 
included a double abstraction of a randomly selected sample (approximately 10%) to ensure 
consistency among abstractors. CaP aggressiveness was defined in PCaP as high aggressive 
(Gleason sum ≥8 or PSA >20 ng/mL or Gleason sum ≥7 and clinical stage T3–T4), low 
aggressive (Gleason sum < 7 and clinical stage T1-T2 and PSA <10 ng/ml), and 
intermediate aggressive (all others). These categories were used in case-case analyses 
contrasting high aggressive CaP cases with low/intermediate aggressive cases.
Dietary Carotenoid Intake
Dietary carotenoid intakes were assessed using the National Cancer Institute Diet History 
Food-frequency Questionnaire (NCI-DHQ) (23), which was modified to include Southern 
foods. The modified 144-item DHQ solicited detailed information about usual diet in the 
year before the diagnosis of CaP, which included frequency of food intake, portion size, and 
food preparation methods. Responses to the questions were linked to an updated NCI 
nutrient database through which the research subjects’ usual daily intakes of various 
nutrients including α– and β–carotene, β–cryptoxanthin, lutein-zeaxanthin and lycopene 
were estimated using NCI Diet*Calc software (22).
Data on supplemental carotenoid intake were derived using a standardized questionnaire 
(24). Research subjects were asked about multivitamin and single-nutrient supplement use in 
the year preceding their diagnosis of CaP (no, less than once per week, yes) and those who 
answered “yes” were queried about the frequency of use (1–2, 3–4, 5–6, 7 days/week). 
Responses to the questionnaire were recorded by nurse interviewers who also undertook an 
inventory of nutrient contents and listed dose information from manufacturer label of each 
supplement type. When the supplement bottle was not available, research subjects were 
asked the usual dose taken. Average daily intakes of supplemental β–carotene, lutein and 
lycopene were estimated based on contributions from multivitamin and single-nutrient 
supplements as frequency (days per week) x dose (in µg) x number of pills taken at each 
time / 7. Total daily intake of β–carotene, lutein and lycopene were estimated as the sum of 
intakes from diet and supplement (diet + supplement) for each carotenoid.
Adipose Tissue Carotenoid Concentration
Approximately two grams of subcutaneous abdominal adipose tissue samples were obtained 
from consenting research subjects by trained nurses after anesthetizing the overlying skin 
with 2% lidocaine solution. PCaP research nurses, who were specifically trained for adipose 
tissue sampling, followed a standardized procedure that inserted a 15-gauge needle into the 
subcutaneous fat and applied negative pressure using a 15 ml vacutainer tube after prepping 
the overlying skin. The aspirated tissue was trapped in the needle and luer lock adapter, 
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which was placed in a separate cryovial and transported on ice via overnight courier to a 
designated storage facility where aliquots were prepared and stored at –80°C until assayed. 
Individual carotenoids were measured using high-performance liquid chromatography 
(HPLC) at the nutrition analyses laboratory of Craft Technologies, Inc. (Wilson, NC) using 
methods described by Craft et al. (25). The adipose tissue concentrations of α–carotene, cis- 
and trans-β–carotene, α–cryptoxanthin, β-cryptoxanthin, lutein, zeaxanthin, and cis- and 
trans-lycopene were quantified at minimum detection limit 0.003 µg/g of tissue.
Statistical Analyses
Before any analysis was performed, research subjects with incomplete data on CaP 
aggressiveness (n = 94) and those with implausible values for energy intake (< 500 or ≥6000 
kcal/day, n = 71) were excluded from the total PCaP sample of 2267. The remaining 2,102 
research subjects were included in the analyses; however, data on adipose tissue carotenoid 
levels were available for only 939 cases (EAs n = 581, AAs n = 358). All analyses were 
performed separately for AAs and EAs.
Descriptive statistics were expressed as means for continuous variables and proportions for 
categorical variables using t-tests and Chi-square tests, respectively. The carotenoid 
variables were categorized into tertiles according to distribution among low/intermediate 
aggressive cases, and unconditional logistic regression was used to estimate odds ratios 
(ORs) and 95% confidence intervals (95% CIs) for high aggressive CaP for increasing 
tertiles with the lowest tertile as the referent group. Trend tests were performed by assigning 
each tertile its median value expressed as a continuous variable in the logistic regression 
models. All associations were examined in crude (age-adjusted) and multivariable-adjusted 
models. The following known or suspected risk factors for CaP aggressiveness were 
considered for inclusion in the multivariable-adjusted models: age (continuous), body mass 
index (BMI, kg/m2); family history of CaP in a first degree relative (none vs. at least one); 
pre-diagnostic PSA screening history (0, 1–7, >7 screenings); number of comorbidities (0, 1, 
2, ≥3); whether CaP treatment had started at the time of the interview (yes, no); smoking 
status (never, former, current); education (less than high school education, high school 
graduate/some college, college graduate); annual household income (<$20,000, $20,001-
$40,000, $40,001-$70,000, >$70,000); NSAIDs use in the five years prior to diagnosis (yes, 
no); physical activity in the year prior to diagnosis [total metabolic equivalents (METs) of 
light, moderate, and vigorous exercise categorized as: ≤10.2, 10.3–29.0, >29.0 METs/week]; 
dietary fat intake (grams/day); alcohol intake (grams/day) and study site (NC, LA). 
Covariates that altered ORs of the main exposure variables by at least 10% were included in 
a full model for final model selection using the backward elimination method. Models were 
constructed separately by race. When a factor was determined to be a confounder in one race 
but not the other, that factor was included in each of the race-stratified analyses. Of the 
potential covariates, age, PSA screening history, BMI, smoking status, education, income, 
NSAIDs use, total fat intake, and study site were included in the final multivariable-adjusted 
models. Further adjustment for family history of CaP, comorbidities, and CaP treatment 
status were done in models examining associations between adipose carotenoid levels and 
CaP aggressiveness.
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Stratified analyses by BMI (<24.9, normal weight; 25–29.9, overweight; ≥30 kg/m2, obese) 
and smoking status were performed to evaluate whether the associations were modified by 
these factors. The evaluation of effect modification included interaction terms between BMI 
and smoking status variables and each of the carotenoids examined by likelihood ratio tests 
based on models with and without an interaction term. All statistical tests were two-sided 
and p-values less than 0.05 were considered statistically significant except for interaction p-
values in the exploratory stratified analyses, where significance level was set at 0.10 in order 
to accommodate the small sample size of the stratified groups. All analyses were performed 
using SAS® version 9.3 (SAS Institute, Cary, NC).
Results
In both AAs and EAs, research subjects with high aggressive CaP were older and less 
educated compared to those with low/intermediate aggressive CaP (Table I). EA research 
subjects with high aggressive CaP had a slightly higher BMI and were more likely to have 
started treatment for CaP compared to EAs with low/intermediate aggressive CaP. AA 
research subjects with high aggressive CaP tended to have a higher reported intake of energy 
and dietary fat, were less likely to have had at least one pre-diagnostic PSA screening, and 
included a greater proportion of current and former smokers and low incomes compared to 
AAs with low/intermediate aggressive CaP.
Mean difference in carotenoid levels by CaP aggressiveness
Reported daily intake of carotenoids varied significantly between AAs and EAs (Table II). 
EAs tended to have higher intakes of α–carotene, supplemental β–carotene and lutein, and 
higher intake of lycopene from diet and supplements. AAs had higher dietary intakes of β–
carotene, β–cryptoxanthin and lutein + zeaxanthin. Of note, rates of supplemental carotenoid 
intake were higher in EAs than AAs. For example, among AAs, 23% of AAs reported 
supplemental intake of lycopene and 30% reported supplemental β-carotene intake, while 
among EAs, 28% reported supplemental lycopene intake and 42% reported supplemental β-
carotene intake. Adipose tissue carotenoid levels were generally higher in EAs than AAs 
with significant differences in the levels of zeaxanthin and lycopene (both cis and trans 
isoforms). Few significant differences in unadjusted mean carotenoid intake or adipose 
levels were observed by CaP aggressiveness among EAs or AAs.
Dietary and supplemental carotenoid intake and CaP aggressiveness
Substantial differences in carotenoid intake between AAs and EAs required the use of 
different cut-points to categorize each carotenoid by race; hence, results are presented 
separately for AAs and EAs (Table III). Among EAs, dietary lycopene intake was associated 
with a decrease in odds of high aggressive CaP; OR was 0.55 (95% CI: 0.34–0.89, Ptrend = 
0.02) in the highest versus lowest tertile after adjustment for multiple covariates. Although 
supplemental lycopene use was not associated with CaP aggressiveness among EAs, total 
lycopene intake from diet and supplements was related inversely to high aggressive CaP (OR 
= 0.56, 95% CI: 0.34–0.90, highest versus lowest tertile, Ptrend = 0.03). These significant 
associations were not observed among AAs. However, dietary β–cryptoxanthin intake was 
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associated with 45% lower odds of high aggressive CaP among AAs only. None of the other 
carotenoids was significantly associated with CaP aggressiveness in either race.
Adipose tissue carotenoid levels and CaP aggressiveness
Evaluation of associations between adipose tissue carotenoid levels and CaP aggressiveness 
showed a marginally significant inverse linear trend toward lower odds of high aggressive 
CaP for the associations of adipose α–carotene (Ptrend = 0.07) and lycopene (cis + trans, 
Ptrend = 0.11) among EAs. No associations were observed between adipose carotenoid levels 
and CaP aggressiveness among AAs. Research subjects with data on adipose tissue 
carotenoid levels were similar to those without data on adipose carotenoids in the extent of 
CaP aggressiveness; however, they differed in BMI, race, CaP screening history, education, 
income, smoking status and study site (Supplemental Table I). These differences 
necessitated an alternate analysis of dietary carotenoid intake and CaP aggressiveness among 
research subjects who had adipose carotenoid data. The results from this analysis were 
similar to those presented in Table III (Supplementary Table II), which suggested minimal 
impact of missing adipose tissue data on the observed associations. In the stratified analyses, 
the associations between all measured carotenoids and CaP aggressiveness did not vary by 
smoking status or BMI (data not shown).
Discussion
This population-based study examined associations between carotenoid intake and adipose 
tissue carotenoid levels in relation to CaP aggressiveness among AAs and EAs in North 
Carolina and Louisiana. Inverse associations were observed between intake of lycopene and 
CaP aggressiveness among EAs, and between β–cryptoxanthin intake and CaP 
aggressiveness among AAs. Marginally significant linear trends in the direction of reduced 
odds of high aggressive CaP were observed for higher adipose abdominal tissue levels of α–
carotene and lycopene (cis + trans) among EAs only. Subgroup analysis did not show 
evidence of effect modification by smoking status or BMI in either race.
A number of studies have suggested that carotenoid intake may play a beneficial role in CaP 
incidence; however, the overall evidence remains inconclusive (reviewed in (7,8)). 
Carotenoids are broadly categorized as pro-vitamin A (i.e., α–carotene, β–carotene, and β–
cryptoxanthin) or non-pro-vitamin A (i.e., lutein, zeaxanthin and lycopene) depending on 
whether they are converted into retinol in the body (26). Both groups of carotenoids have 
been shown in in vitro and in vivo studies to have biological functions that could prevent or 
suppress the progression of cancer (27). Proposed mechanisms by which carotenoids may 
influence CaP aggressiveness include modulation of gene expression, induction of apoptosis, 
suppression of angiogenesis, and enhancement of antitumor immune responses (26,27). 
Equivocal findings in the literature may result from the focus on CaP incidence (6–8,19,28). 
Moreover, populations included in prior studies were predominantly of European decent, 
therefore the study results may not be necessarily applicable to AAs. Although the current 
study shows some differences in carotenoid associations with CaP aggressiveness between 
AAs and EAs, comparisons were made within each race. This analytic approach minimizes 
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confounding by unmeasured sociocultural factors, and possibly, biological factors that are 
inherently different between AAs and EAs (21,29).
The current finding for lycopene among EAs is consistent with previous studies that 
suggested that lycopene may be beneficial in reducing the risk and aggressiveness of CaP. In 
a prospective cohort study of male health professionals, higher lycopene intake was 
associated 21% lower risk of CaP and higher intake of tomato and tomato products (the 
primary sources of lycopene) also was associated with 53% reduced risk of advanced CaP 
(18). Gann et al. (30) reported a lower risk of aggressive CaP in men with high plasma 
lycopene levels. In another prospective study, Kirsh et al. (13) reported an inverse 
association between lycopene intake and CaP incidence among men with a family history of 
CaP. Reports from some case-control studies suggest that lycopene may reduce the risk of 
CaP (19,31), although others have failed to show an association (14,32). In addition to 
tomatoes and tomato-based foods, lycopene can be obtained in modest amounts from 
watermelon, guava, and papaya. Lycopene is considered the most potent antioxidant 
carotenoid because of its singlet oxygen quenching ability (33). The bioavailability of 
lycopene increases with thermal treatment of tomatoes, such as steaming, boiling or stewing, 
processing of tomatoes with oil, or simultaneous ingestion of tomato-based foods and fat 
(34). Thus, the potential benefits of lycopene depend on food processing and dietary habits, 
which may partly explain the discrepancy in lycopene associations between AAs and EAs. 
The consumption of lycopene from food and supplements, and adipose lycopene 
concentrations were higher in EAs than AAs (Table II), which suggest that the potential 
benefits of lycopene in relation to CaP aggressiveness may be acquired only at higher levels 
of intake.
The difference in lycopene associations between AAs and EAs also may have been 
influenced by gene-diet interactions that may vary by race. Goodman et al. (35), reported 
that polymorphic variants in XRCC1, a gene involved in base excision repair of DNA 
damage, may be associated with reduced ability of lycopene to decrease the risk of CaP. 
Accumulating evidence suggests that lycopene may play a more critical role in angiogenesis, 
tumor migration and apoptosis (36,37), molecular pathways that are relevant to CaP 
aggressiveness (38). Therefore, evaluating race-specific interactions between lycopene and 
functional polymorphisms in genes involved in these pathways may help unravel how 
lycopene might influence differentially CaP aggressiveness in different population 
subgroups.
β–cryptoxanthin, which is commonly found in tangerines, oranges, grapefruit, mangoes, 
fruit juices and red peppers (39), was inversely associated with CaP aggressiveness, but only 
among AAs, whose intake of β–cryptoxanthin were 37% higher than EAs (Table II). Studies 
have reported inverse (31,40) or positive (28,41) associations between β–cryptoxanthin and 
CaP risk. Reviews of the literature do not provide compelling evidence for or against a 
protective association between β–cryptoxanthin and CaP (6–8). Perhaps examining β–
cryptoxanthin associations with different CaP phenotypes, as done in this study, may help 
delineate the role of β–cryptoxanthin in prostate carcinogenesis. The associations of α–
carotene, β–carotene and lutein + zeaxanthin, and CaP incidence also have varied across 
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studies (6,18–20). Evaluations of these carotenoids in relation to CaP aggressiveness are rare 
(10,12,14), but evolving, and may help clarify their role in CaP.
Adipose tissue biomarkers of nutrient intake have been used to assess disease risk (42,43) 
and continues to receive increased attention because of the ability of adipose tissue to reflect 
long-term nutritional status. However, the uptake and turnover rates of carotenoids in 
adipose tissues remain unclear (44). The suggestion that higher adipose α–carotene and 
lycopene concentrations are related inversely to CaP aggressiveness warrants further 
investigation in larger studies, partly because of the possibility that adipose α–carotene and 
lycopene may have acted as markers for increased consumption of fruits and vegetables or as 
surrogates for a healthy lifestyle in general.
Cigarette smoking has been associated with depletion of circulating carotenoid levels (45) 
and high BMI appears to increase the body’s carotenoids requirement (46); however, neither 
of these factors were found to have modifying effect on the associations between carotenoids 
intake and CaP aggressiveness. This is the first study to examine effect modification of 
carotenoids by smoking or BMI in relation to CaP aggressiveness. Some studies have 
suggested that β–carotene supplements may increase the risk of CaP among smokers (15). 
Thus, further evaluation in larger samples is needed to help tease out the potential interaction 
between carotenoids intake and smoking or BMI in relation to CaP aggressiveness.
Diet was assessed using a food frequency questionnaire. These structured instruments may 
be biased according to response sets (47) which, in turn, may be related to psychological 
traits that either exert a direct effect on cancer outcomes or indirectly affect other factors that 
may influence carcinogenesis (48). Other limitations of the current study include the fact 
that carotenoids likely do not act alone, and thus, the results reported here may reflect 
interactions among individual carotenoids or interactions with other food components or 
genetic variants (35). Because the diet assessment instrument was administered after 
diagnosis of CaP, post-diagnosis changes in dietary patterns could have influenced dietary 
recall and may have affected the results to some extent. This should be considered in the 
interpretation of results. Moreover, self-report of diet can be problematic, especially when 
asking research subjects to report dietary intake from the year prior to completing the 
questionnaire. Such recall inaccuracies would have resulted in non-differential 
misclassification because the research subjects were not likely to consider their disease 
aggressiveness in answering questions relating to food and supplements intake. Furthermore, 
laboratory personnel involved in the analyses of adipose carotenoid levels were blinded to 
the CaP attributes of the samples. Therefore, non-differential, rather than differential, 
misclassification may have attenuated the ORs to some extent. Some carotenoids may exert 
their beneficial effects in the early stages of carcinogenesis (27). The one-year reference 
period for the dietary and supplement use assessment may not be etiologically relevant to 
CaP, but can provide an estimate of usual dietary patterns (23); adipose tissue concentrations 
reflect longer-term exposure. Metabolic alterations in nutritional status of cancer patients 
have been documented (44) and therefore cancer-induced metabolic abnormalities may have 
affected the measured carotenoid levels. However, it has been observed that adipose tissue 
carotenoid levels are less susceptible to changes due to the presence of a tumor (49). 
Adipose carotenoid levels have been correlated inversely with body fat percentage (50). The 
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potential confounding effect of body fat burden was considered by adjusting for BMI (in the 
BMI unstratified analyses). Despite these limitations, the design of the study uniquely 
captures the complex pathological and clinical attributes of CaP, and the findings of this 
analysis add to the limited knowledge of the potential role of carotenoids in CaP 
aggressiveness within specific race groups.
Conclusions
This analysis shows a statistically significant inverse association between lycopene intake 
and CaP aggressiveness among EAs, and between β–cryptoxanthin and CaP aggressiveness 
among AAs. There was a suggestion that higher adipose tissue α–carotene and lycopene (cis 
+ trans) levels also were inversely related to CaP aggressiveness among EAs. The results 
suggest that certain carotenoids may have greater beneficial impact among obese individuals 
with the possibility of detrimental effects among normal weight men, findings that warrant 
further investigation in larger studies. Although some of the findings vary by race, this was 
likely due to the variations in the levels of carotenoid intake between AAs and EAs. Overall, 
the findings support suggestions that a higher consumption of fruits and vegetables, which 
are the main sources of carotenoids, may be inversely associated with CaP aggressiveness.
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